SCHEMBL14133265

SCHEMBL14133265

Cc1ccc(C2CC(c3ccc(NS(C)(=O)=O)cc3)=NN2C(=O)C(C)(C)C)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 5/20 0.76
▸ BECN1 Q14457 5/20 0.76
▸ KDM4E B2RXH2 9/20 0.74
▸ ALDH1A1 P00352 8/20 0.74
▸ PKM P14618 6/20 0.74
▸ GLA P06280 4/20 0.74
▸ GAA P10253 3/20 0.74
▸ HPGD P15428 3/20 0.74
▸ MAPT P10636 3/20 0.71
▸ KMT2A Q03164 2/20 0.69
▸ NPC1 O15118 1/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ HTT P42858 2/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.58
▸ PTGS2 P35354 1/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ POLB P06746 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ CYP3A4 P08684 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14133434 0.91 KDM4E (0.68) BCL2BECN1KDM4EALDH1A1PKM
SCHEMBL14132770 0.91 ALDH1A1 (0.73) BCL2BECN1KDM4EALDH1A1PKM
SCHEMBL14133616 0.89 KDM4E (0.66) BCL2BECN1KDM4EALDH1A1PKM
SCHEMBL14133880 0.88 BCL2 (0.80) BCL2BECN1KDM4EALDH1A1PKM
SCHEMBL23269375 0.86 BCL2 (1.00) BCL2BECN1KDM4EALDH1A1PKM
SCHEMBL14133622 0.85 KDM4E (0.80) BCL2BECN1KDM4EALDH1A1PKM
SCHEMBL14133349 0.85 KDM4E (1.00) BCL2BECN1KDM4EALDH1A1PKM
SCHEMBL14133593 0.84 ALDH1A1 (0.69) BCL2BECN1KDM4EALDH1A1PKM
SCHEMBL14133320 0.83 KDM4E (0.71) BCL2BECN1KDM4EALDH1A1PKM
SCHEMBL14133336 0.83 KDM4E (1.00) BCL2BECN1KDM4EALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 BCL2 2632/4885BECN1 3273/4885KDM4E 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback